Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

phenobarbitone sodium (may only be prescribed for the treatment of epilepsy)

NULL

phenobarbitone sodium (may only be prescribed for the treatment of epilepsy) (NULL) is an FDA-listed pharmaceutical active ingredient.

TGA: approved
Patents linked 20
Pipeline programs 39
News articles 1
Drug details — phenobarbitone sodium (may only be prescribed for the treatment of epilepsy)
Class
—
Route
—
Patents
20
Programs
39
Data quality
0.78
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

phenobarbitone sodium (may only be prescribed for the treatment of epilepsy) (NULL) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN phenobarbitone sodium (may only be prescribed for the treatment of epilepsy)
Brand NULL

Approval history

Authority Status Date
TGA approved —

Recent coverage

View all news
Axsome FDA Approval for Alzheimer's Agitation Drug
Critical impact Newsagitation associated with Alzheimer's diseaseMay 3, 2026

Axsome FDA Approval for Alzheimer's Agitation Drug

FDA · agitation associated with Alzheimer's disease · 6 min

Axsome Therapeutics has received FDA approval for a new treatment for agitation associated with Alzheimer's disease. This landmark decision addresses a critical unmet need and marks a significant step forward for the company and Alzheimer's patient care.

Dr. Priya Nandakumar

Pipeline programs

Search pipeline
  1. 42-1703 Phase 3 · Aquestive Therapeutics · Epilepsy
  2. Brivaracetam Phase 3 · Ucb Pharma S.P.A · Epilepsy
  3. GWP42003-P Phase 3 · Jazz Pharmaceuticals Ireland · Epilepsy
  4. GWP42003-P 20 mg/kg/Day Dose Phase 3 · Jazz Pharmaceuticals Ireland · Epilepsy
  5. Intravenous Carbamazepine (IV CBZ) Phase 3 · LIGAND PHARMACEUTICALS · Epilepsy
  6. Levetiracetam Phase 3 · Ucb Pharma S.P.A · Epilepsy
  7. XEN496 Phase 3 · Xenon Pharmaceuticals · Epilepsy
  8. Zonisamide Phase 3 · Eisai · Epilepsy

Related patents

Browse patents

  1. US 12304908

    Azabenzimidazoles and their use as AMPA receptor modulators

    Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12178811

    Methods of treating depressive disorders

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12171759

    Methods and uses for treating anhedonia

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11957675

    Methods and uses for treating anhedonia

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11325902

    Benzenesulfonamide compounds and their use as therapeutic agents

    Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11299490

    Benzenesulfonamide compounds and their use as therapeutic agents

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11203572

    Substituted benzamides and methods of use thereof

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11174268

    Benzenesulfonamide compouds and their use as therapeutic agents

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11149002

    Therapeutic compounds and methods of use thereof

    Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11135214

    Methods for enhancing the bio availability and exposure of a voltage-gated potassium channel opener

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11130726

    Therapeutic compounds and methods of use thereof

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10899732

    Substituted benzamides useful as sodium channel blockers

    Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10815229

    Benzenesulfonamide compounds and their use as therapeutic agents

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10787446

    Therapeutic compounds and methods of use thereof

    Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10766858

    Substituted benzamides and methods of use thereof

    Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10745392

    Benzenesulfonamide compounds and their use as therapeutic agents

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10662184

    Benzenesulfonamide compounds and their use as therapeutic agents

    Expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10526285

    Therapeutic compounds and methods of use thereof

    Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10513526

    Solid state forms of spiro-oxindole compounds

    Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10457654

    Therapeutic compounds and methods of use thereof

    Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is phenobarbitone sodium (may only be prescribed for the treatment of epilepsy)?

phenobarbitone sodium (may only be prescribed for the treatment of epilepsy) (NULL) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for phenobarbitone sodium (may only be prescribed for the treatment of epilepsy)?

NULL is a marketed brand name for phenobarbitone sodium (may only be prescribed for the treatment of epilepsy). Check FDA Drugs@FDA for the current US label holder and prescribing information.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.